Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development.

MLA

Tran, Melissa A., et al. “Combining Nanoliposomal Ceramide with Sorafenib Synergistically Inhibits Melanoma and Breast Cancer Cell Survival to Decrease Tumor Development.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 14, no. 11, June 2008, pp. 3571–81. EBSCOhost, https://doi.org/10.1158/1078-0432.CCR-07-4881.

APA

Tran, M. A., Smith, C. D., Kester, M., & Robertson, G. P. (2008). Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 14(11), 3571–3581. https://doi.org/10.1158/1078-0432.CCR-07-4881

Chicago

Tran, Melissa A, Charles D Smith, Mark Kester, and Gavin P Robertson. 2008. “Combining Nanoliposomal Ceramide with Sorafenib Synergistically Inhibits Melanoma and Breast Cancer Cell Survival to Decrease Tumor Development.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 14 (11): 3571–81. doi:10.1158/1078-0432.CCR-07-4881.